VERA THERAPEUTICS INC (VERA)

Company Profile

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 49 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. The firm is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants.

Company Info

VERA THERAPEUTICS INC

8000 Marina Boulevard,, Suite 120

Brisbane California CALIFORNIA 14623

P: 16507700077

CEO: Marshall Fordyce

Employees: 49

Website: https://veratx.com/